Form 4: Apogee Therapeutics' Chief Medical Officer Sells Shares

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold shares of common stock on August 7, 2024, under a pre-arranged trading plan.

Summary

• On August 7, 2024, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 27, 2023.
• A total of 7,335 shares were sold in multiple transactions at varying prices.
• Specifically, 6,523 shares were sold at a weighted average price of $40.47, 142 shares at $41.09, and 670 shares at $42.56.
• Following these transactions, Dambkowski directly owns 287,458 shares of Apogee Therapeutics.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an executive. The pre-planned nature of the sales suggests a neutral sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the pre-planned nature of these sales mitigates this concern.

Future Outlook

The document does not contain any forward-looking statements.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the pre-planned nature of the transaction should mitigate any significant concerns.

Key Dates